Hang Zhang^1,#, Meng-Yuan Chu^1,#, Guohui Lv¹, You-Jie Li¹, Xuhang Liu², Fei Jiao^1,*, Yun-Fei Yan^1,*

BIOCELL, Vol.50, No.1, 2026, DOI:10.32604/biocell.2025.068322 - 23 January 2026

Abstract Objectives: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with limited understanding of lncRNA-driven mechanisms in tumor progression. This study aimed to identify differentially expressed lncRNAs in NSCLC tissues and elucidate the functional role of the significantly upregulated RP3-340N1.2 in promoting malignancy. Methods: RNA sequencing was used to screen dysregulated lncRNAs. RP3-340N1.2 was functionally characterized via gain/loss-of-function assays in NSCLC cells, assessing proliferation, migration, and macrophage polarization. Mechanisms of interleukin 6 (IL-6) regulation were explored using cytokine profiling, Actinomycin D assays, and RNA Immunoprecipitation (RIP) assays to study RP3-340N1.2 interactions with… More >

Ruoxue Cai^1,#, Shuyi Hu^2,#, Feiyang Li², Huanhuan Sha^3,*, Guoren Zhou^2,*, Ying Fang³

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.070893 - 19 January 2026

Abstract Objective: To determine whether immunotherapy can bring new hope for patients with limited-stage small-cell lung cancer (LS-SCLC). We conducted this retrospective study to evaluate whether immunotherapy can achieve better efficacy in LS-SCLC patients. Methods: We evaluated 122 LS-SCLC patients who received concurrent chemoradiotherapy (CCRT) or sequential chemoradiotherapy (SCRT) (Group A) and immunotherapy combined with CCRT/SCRT followed by immunotherapy (Group B), to assess the objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). Factors affecting prognosis were also explored using Cox analysis. The prognosis of patients with type 2 diabetes and patients with… More >

Marco Siringo^1,2,#,*, Michela De Meo^1,#, Alain Jonathan Gelibter³, Chiara Nicolazzo^4,5,§, Paola Gazzaniga^5,§

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.069832 - 19 January 2026

Abstract Objectives: Although immune checkpoint inhibitors (ICIs) and targeted therapies have reshaped treatment non-small cell lung cancer (NSCLC) paradigms, prognosis remains poor for many patients due to delayed diagnosis and resistance mechanisms. Liquid biopsy offers a minimally invasive approach to monitoring tumor evolution. Among circulating biomarkers, circulating tumor cells (CTCs) and cancer-associated macrophage-like cells (CAM-Ls) may provide complementary prognostic insights. The study aimed to evaluate the prognostic role of CTC and CAM-Ls dynamic in metastatic NSCLC patients. Methods: We retrospectively analyzed 77 patients with metastatic NSCLC who underwent CTC and CAM-L evaluation via the CellSearch® system… More >

Sha Hu^1,2,#, Wenjing Wang^1,#, Qianfang Hu^3,#, Rujuan Zheng^1,2, Qinghe Huang^1,2, Hui Shi^1,2, Xinyuan Ding^3,*, Wenjuan Wang^1,2,*, Zengyan Zhu^1,2,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.068967 - 19 January 2026

Abstract Objectives: Acquired resistance to paclitaxel represents a critical barrier to the effective chemotherapy of non-small cell lung cancer (NSCLC). The present study aimed to elucidate the molecular and pharmacological mechanisms promoting paclitaxel resistance in NSCLC and to explore potential strategies for overcoming this resistance. Methods: Here, we report an integrated pharmacological and analytical approach to quantify paclitaxel disposition and overcome resistance in a A549/TAX cell model (paclitaxel-resistant A549 cells). Results: Cell counting kit-8 (CCK-8) assay, colony formation, and apoptosis assays confirmed that A549/TAX cells exhibited marked resistance to paclitaxel relative to parental A549 cells. Based on… More >

Khanh Toan Nguyen^1,*, Thi Huong Pham^1,2, Van Lam Ngo¹, Thi Thuy My Nguyen¹, Thi Dao Nguyen¹, Khanh Hung Truong¹, Van Nhat Nguyen¹, Van Thanh Le¹, Ba Duc Ho¹, Thi Phuong Thao Nguyen¹, Thi Ha Phuong Nguyen¹, Thi My Linh Dinh¹, Thi Hong Anh Vo¹, Thi Thuy Phan¹, Thi Hai Yen Le¹, Thi Nhung Ngo¹, Khanh Ha Nguyen¹

Oncology Research, Vol.33, No.12, pp. 4013-4028, 2025, DOI:10.32604/or.2025.069281 - 27 November 2025

Abstract Objective: Patients with stage III non-small cell lung cancer (NSCLC) present with a heterogeneous disease profile and often require multifaceted treatment strategies. This research aimed to investigate the demographic features, therapeutic patterns, and survival outcomes of such patients in Vietnam. Methods: A retrospective descriptive study was conducted on 731 patients diagnosed with stage III NSCLC American Joint Committee on Cancer (AJCC) 8th edition, at Nghe An Oncology Hospital from January 2018 to August 2024. Descriptive statistics summarized baseline and treatment characteristics. We calculated progression-free survival (PFS) and overall survival (OS) through the Kaplan–Meier approach and… More >

Xiangyu Yan^1,#, Yusheng Jin^1,#, Yan Yuan¹, Xubaihe Zhang¹, Jiayi Li¹, Ying Xu¹, Yangyang Ge², Anqing Wu^1,*

BIOCELL, Vol.49, No.10, pp. 1929-1946, 2025, DOI:10.32604/biocell.2025.066935 - 22 October 2025

Abstract Objectives: Fractionated radiotherapy represents a standardized and widely adopted treatment modality for cancer management, with approximately 40% of non-small cell lung cancer (NSCLC) patients receiving it. However, repeated irradiation may induce radioresistance in cancer cells, reducing treatment effectiveness and raising recurrence risk. The long noncoding RNA CRYBG3 (lncRNA CRYBG3), which is upregulated in lung cancer cells after X-ray irradiation, contributes to the radioresistance of NSCLC cells by promoting wild-type p53 protein degradation. This study aims to elucidate the mechanism of fractionated irradiation-induced radioresistance, in which lncRNA CRYBG3 regulates radiation-induced mitochondrial damage and reactive oxygen species… More >

Eleni Kokkotou^*, Andriani Charpidou, Nikolaos Syrigos

Oncology Research, Vol.33, No.10, pp. 2657-2672, 2025, DOI:10.32604/or.2025.066228 - 26 September 2025

Abstract Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) serve an essential role in tumor angiogenesis and have emerged as potential therapeutic targets in lung cancer. This review explores the significance of serum VEGF levels as a predictive biomarker in non-small cell lung cancer (NSCLC). The VEGF family, consisting of VEGFA, VEGFB, VEGFC, VEGFD, and placenta growth factor (PlGF), engages with specific receptors, including tyrosine kinase receptors (VEGFR-1, VEGFR-2, and VEGFR-3) and neuropilin receptors (NRP-1 and NRP-2), to promote angiogenesis and lymphangiogenesis. VEGF-A, the primary component of the VEGF family, binds to VEGFR-2 to stimulate… More >

Junqi Guo^1,2, Yun Yang^1,2, Wei Zhao^1,2, Zhonghai Yan³, Xia Yang⁴, Yunfei Yan^1,2, Ruimin Hao^1,2, Jinxia Hu^1,2,*, Fei Jiao^1,2,*

BIOCELL, Vol.49, No.9, pp. 1797-1797, 2025, DOI:10.32604/biocell.2025.071013 - 25 September 2025

Abstract This article has no abstract. More >

Oncology Research Editorial Offfce

Oncology Research, Vol.33, No.9, pp. 2599-2599, 2025, DOI:10.32604/or.2025.071884 - 28 August 2025

Abstract This article has no abstract. More >

Xi Qin^1,#, Yulan Liu^1,#, Lin Zhu², Yunyan Mo¹, Jing Zhang³, Zhuchun Jiang⁴, Dongning Huang⁵, Xinrong Hu⁶, Jingzhang Li⁷, Quanfang Chen⁸, Feng Xue^1,*

Oncology Research, Vol.33, No.9, pp. 2451-2462, 2025, DOI:10.32604/or.2025.064119 - 28 August 2025

Abstract Background: The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases. Methods: The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint. Adverse events… More >